Degradation of AZGP1 suppresses apoptosis and facilitates cholangiocarcinoma tumorigenesis via TRIM25 DOI Creative Commons

Hyeseon Yun,

Hong‐Rae Jeong,

Do Yeon Kim

et al.

Journal of Cellular and Molecular Medicine, Journal Year: 2024, Volume and Issue: 28(3)

Published: Jan. 6, 2024

Abstract Alpha‐2‐Glycoprotein 1, Zinc‐binding (AZGP1, ZAG) is a secreted protein that synthesized by adipocytes and epithelial cells; it downregulated in several malignancies such as breast, prostate, liver lung cancers. However, its function remains unclear cholangiocarcinoma (CCA). Here, we evaluated the impact AZGP1 CCA using Gene Expression Omnibus (GEO) GEPIA. In addition, analysed expression quantitative reverse transcription PCR western blotting. of was nearly deficient patients cell lines associated with poor prognosis. overexpression upregulated apoptosis markers. Co‐immunoprecipitation experiments showed interacts tripartite motif‐containing 25 (TRIM25), tissue microarray bioinformatic analysis negatively correlated TRIM25 CCA. Thereafter, knockdown led to upregulation induced cancer apoptosis. targets for degradation catalysing ubiquitination. significantly suppressed tumour growth xenograft mouse model. This study findings suggest potential therapeutic target or diagnostic biomarker treating

Language: Английский

FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis? DOI Creative Commons
Paulina Chmiel, Katarzyna Gęca, Karol Rawicz‐Pruszyński

et al.

Cells, Journal Year: 2022, Volume and Issue: 11(23), P. 3929 - 3929

Published: Dec. 5, 2022

Cholangiocarcinomas (CCAs) are rare but aggressive tumours with poor diagnosis and limited treatment options. Molecular targeted therapies became a promising proposal for patients after progression under first-line chemical treatment. In light of an escalating prevalence CCA, it is crucial to fully comprehend its pathophysiology, aetiology, possible targets in therapy. Such knowledge would play pivotal role searching new therapeutic approaches concerning diseases’ symptoms their underlying causes. Growing evidence showed that fibroblast growth factor/fibroblast factor receptor (FGF/FGFR) pathway dysregulation involved variety processes during embryonic development homeostasis as well tumorigenesis. CCA known close correlation the FGF/FGFR targeting this axis has been proposed guidelines. Bearing mind significance molecular different neoplasms, seems most reasonable move towards intensive research testing on these case CCA. However, there still need more data covering topic. Although positive results many pre-clinical clinical studies discussed review, difficulties lie ahead. Furthermore, review presents up-to-date literature regarding outcomes latest discussion over future directions FGFR-directed

Language: Английский

Citations

23
MUC1 induces the accumulation of Foxp3+ Treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the EGFR/PI3K/Akt signaling pathway DOI
Guofeng Zhang,

Zheng Ge,

Haipeng Zhang

et al.

International Immunopharmacology, Journal Year: 2023, Volume and Issue: 118, P. 110091 - 110091

Published: April 3, 2023

Language: Английский

Citations

14
Role and Therapeutic Potential for Targeting Fibroblast Growth Factor 10/FGFR1 in Relapsed Rheumatoid Arthritis DOI Creative Commons

Xiaohui Meng,

Zechuan Chen, Teng Li

et al.

Arthritis & Rheumatology, Journal Year: 2023, Volume and Issue: 76(1), P. 32 - 47

Published: Aug. 19, 2023

Fibroblast-like synoviocytes (FLSs) contribute to inflammation and joint damage in rheumatoid arthritis (RA). However, the regulatory mechanisms of FLSs relapse remission RA remain unknown. Identifying FLS heterogeneity their underlying pathogenic roles may lead discovering novel disease-modifying antirheumatic drugs.

Language: Английский

Citations

14
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma DOI Creative Commons
Timothy P. DiPeri, Ming Zhao, Kurt W. Evans

et al.

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 80(2), P. 322 - 334

Published: Nov. 14, 2023

Language: Английский

Citations

14
Degradation of AZGP1 suppresses apoptosis and facilitates cholangiocarcinoma tumorigenesis via TRIM25 DOI Creative Commons

Hyeseon Yun,

Hong‐Rae Jeong,

Do Yeon Kim

et al.

Journal of Cellular and Molecular Medicine, Journal Year: 2024, Volume and Issue: 28(3)

Published: Jan. 6, 2024

Abstract Alpha‐2‐Glycoprotein 1, Zinc‐binding (AZGP1, ZAG) is a secreted protein that synthesized by adipocytes and epithelial cells; it downregulated in several malignancies such as breast, prostate, liver lung cancers. However, its function remains unclear cholangiocarcinoma (CCA). Here, we evaluated the impact AZGP1 CCA using Gene Expression Omnibus (GEO) GEPIA. In addition, analysed expression quantitative reverse transcription PCR western blotting. of was nearly deficient patients cell lines associated with poor prognosis. overexpression upregulated apoptosis markers. Co‐immunoprecipitation experiments showed interacts tripartite motif‐containing 25 (TRIM25), tissue microarray bioinformatic analysis negatively correlated TRIM25 CCA. Thereafter, knockdown led to upregulation induced cancer apoptosis. targets for degradation catalysing ubiquitination. significantly suppressed tumour growth xenograft mouse model. This study findings suggest potential therapeutic target or diagnostic biomarker treating

Language: Английский

Citations

5